Netherlands

The Netherlands operates within the European Union regulatory framework, meaning health products are governed by a combination of EU-level legislation and national implementation rules. The primary national authority is the CBG-MEB, which oversees pharmaceutical marketing authorisations obtained via the national procedure (NP) or decentralised procedure (DCP), while the European Medicines Agency (EMA), headquartered in Amsterdam, manages the centralised procedure (CP) applicable to many innovative medicines and biologicals. Medical devices and in vitro diagnostics are regulated under EU Regulation 2017/745 (MDR) and EU Regulation 2017/746 (IVDR), with conformity assessment performed by notified bodies and market surveillance conducted by the IGJ. Digital health solutions are subject to IGJ oversight and must comply with applicable Medical Device Regulations if they qualify as Software as a Medical Device (SaMD). The Netherlands Standardisation Institute (NEN) and the Dutch Healthcare Authority (NZa) further shape technical and reimbursement standards across product categories.

All pharmaceutical submissions must follow the Common Technical Document (CTD) format aligned with ICH guidelines, and applicants seeking a national or decentralised authorisation must designate a local EU-based marketing authorisation holder or a qualified person for pharmacovigilance residing within the EU. For medical devices, manufacturers outside the EU must appoint an authorised representative registered in an EU member state. The Netherlands has been an active early adopter of the EU's EUDAMED database requirements for device registration and traceability. Recent reforms include accelerated access pathways such as the Conditional Reimbursement of Medicines (Voorwaardelijke Toelating) scheme, which allows promising medicines to enter the market under monitored conditions while real-world evidence is collected, and increased emphasis on horizon scanning through the ZonMw national health research and innovation programme.

Public procurement of health products in the Netherlands is primarily coordinated through the Ministry of Health, Welfare and Sport (Ministerie van Volksgezondheid, Welzijn en Sport, VWS), which sets national health policy and budget frameworks. Reimbursement decisions for pharmaceuticals are governed by the Health Insurance Act (Zorgverzekeringswet, Zvw) and administered through the National Health Care Institute (Zorginstituut Nederland, ZIN), which conducts health technology assessments (HTAs) using criteria including clinical effectiveness, cost-effectiveness, and budget impact. Hospital procurement is largely decentralised, carried out by individual hospital trusts and academic medical centres, often aggregated through purchasing cooperatives such as Intrakoop. Tenders for high-volume medicines and medical supplies are frequently issued under EU public procurement directives (2014/24/EU), requiring transparent and competitive bidding processes. The NZa regulates tariffs and contracting between health insurers and care providers, adding another layer of pricing governance.

The Netherlands is a high-income country with a predominantly private health insurance system, so international donor-funded channels such as UNICEF, the Global Fund, USAID, or Gavi are not directly applicable to domestic procurement. However, Dutch companies and institutions actively participate in global health initiatives, and the Netherlands contributes significantly as a donor to these organisations. The private market channel is substantial, with approximately a dozen major health insurers negotiating directly with manufacturers and pharmacy chains for preferred formulary placement and volume-based pricing agreements. There is no formal local manufacturing preference policy in the Netherlands; however, EU-level strategic autonomy initiatives, accelerated by supply chain disruptions experienced during the COVID-19 pandemic, have increased political and regulatory support for European domestic production of critical medicines, active pharmaceutical ingredients, and medical supplies, which may translate into future procurement preferences or incentive frameworks at both national and EU levels.